Affordable Access

deepdyve-link
Publisher Website

MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer.

Authors
  • Ryan, Bríd M1
  • Calhoun, Kara M
  • Pine, Sharon R
  • Bowman, Elise D
  • Robles, Ana I
  • Ambs, Stefan
  • Harris, Curtis C
  • 1 Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4258, USA.
Type
Published Article
Journal
International Journal of Cancer
Publisher
Wiley (John Wiley & Sons)
Publication Date
Dec 01, 2012
Volume
131
Issue
11
Pages
2710–2716
Identifiers
DOI: 10.1002/ijc.27573
PMID: 22487911
Source
Medline
License
Unknown

Abstract

Conflicting reports exist regarding the contribution of SNP309 in MDM2 to cancer risk. Recently, SNP285 was shown to act as an antagonist to SNP309 by overriding the effect of SNP309 on SP1-mediated transcription. Moreover, SNP285 modified the relationship between SNP309 and risk of breast, ovarian and endometrial cancer. We assessed whether SNP285 confounded the effect of SNP309 in lung cancer in a cohort of 720 controls and 556 cases. Our cohort included both Caucasians and African Americans. Neither SNP309 nor SNP285 was associated with lung cancer risk or survival. In addition, removal of individuals who carried the variant C allele of SNP285 did not modify the association between SNP309 with either lung cancer risk or survival. Although an effect of SNP285 has been demonstrated in breast, ovarian and endometrial cancer, our findings do not support a role for this SNP in lung cancer and raise the possibility that the effect of SNP285 is restricted to cancers in women.

Report this publication

Statistics

Seen <100 times